HALO logo
halo search icon
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
CLRB · NAS

Cellectar Biosciences, Inc.

US$3.17

Price Arrow0.11 (3.60%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusHALO AllHALO Consensus ValueHALO Earnings MomentumHALO GrowthHammer BullishHammer Bullish (Realtime)+1
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Cellectar Biosciences, Inc. Overview

CLRB Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About CLRB

icon

Telephone

1.608.441.8120

icon

Address

100 Campus Drive, Florham Park, NJ 07932

Description

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

CLRB Price Chart

Key Stats

Market Cap

US$24.45M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 2.43 - 20.59

Trade Value (12mth)

US$623,574.00

1 week

-0.97%

1 month

7.75%

YTD

-11.82%

1 year

-59.04%

All time high

410345984.00

Key Fundamentals

EPS 3 yr Growth

-93.80%

EBITDA Margin

0.00%

Operating Cashflow

-$23m

Free Cash Flow Return

-175.70%

ROIC

-165.60%

Interest Coverage

0.00

Quick Ratio

3.00

Other Data

Shares Outstanding (Fully Diluted)

4m

HALO Sector

Healthcare

Next Company Report Date

11-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

CLRB Announcements

Latest Announcements

DateAnnouncements
19 May 26
19 May 26
14 May 26
14 May 26
14 May 26

CLRB Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-104.99-36.52-8.35locklocklock
EPS (Fully Diluted)
$locklocklocklock-104.99-41.89-8.35locklocklock
Growth
%locklocklocklock22.365.277.1locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Cellectar Biosciences, Inc. (CLRB:NAS)?
Halo FAQ
The current share price of Cellectar Biosciences, Inc. (CLRB:NAS) is USD$3.17.
What is the 52-week high share price for Cellectar Biosciences, Inc. (CLRB:NAS)?
Halo FAQ
The 52-week high share price for Cellectar Biosciences, Inc. (CLRB:NAS) is USD$20.59.
What is the 52-week low share price for Cellectar Biosciences, Inc. (CLRB:NAS)?
Halo FAQ
The 52-week low share price for Cellectar Biosciences, Inc. (CLRB:NAS) is USD$2.43.
What is the dividend yield for Cellectar Biosciences, Inc. (CLRB:NAS)?
Halo FAQ
Cellectar Biosciences, Inc. (CLRB:NAS) does not pay a dividend.
What was Cellectar Biosciences, Inc. (CLRB:NAS) last dividend payment?
Halo FAQ
Cellectar Biosciences, Inc. (CLRB:NAS) does not pay a dividend.
What is the franking level for Cellectar Biosciences, Inc. (CLRB:NAS)?
Halo FAQ
Cellectar Biosciences, Inc. (CLRB:NAS) has a franking level of 0.00%.
In which sector is Cellectar Biosciences, Inc. (CLRB:NAS) classified?
Halo FAQ
Cellectar Biosciences, Inc. (CLRB:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.